Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opening Session Panel Discussion

Advertisement

Advertisement




Oct
27
Today In Oncology
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors
Impact of Digital Breast Tomosynthesis on Invasive Interval Breast Cancer Rate
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo